|
Treatment patterns and clinical outcomes following endocrine resistance among with HER2-low metastatic breast cancer: Retrospective observational study. |
| |
|
Employment - Daiichi Sankyo Pharmaceutical |
Stock and Other Ownership Interests - Daiichi Sankyo Pharmaceutical |
| |
Kristin M. Zimmerman Savill |
Employment - Cardinal Health |
Stock and Other Ownership Interests - Cardinal Health |
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo Pharmaceutical (Inst); Genentech (Inst); Greenwich Biosciences (Inst); Incyte (Inst); Pfizer (Inst); Teva (Inst) |
| |
|
Employment - Daiichi Sankyo Pharmaceutical |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Employment - Daiichi Sankyo, Inc. |
| |
|
Employment - Cardinal Health |
Leadership - Cardinal Health |
Stock and Other Ownership Interests - Cardinal Health |